D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional)

The Data Science Track Award for Research Transition (D-START) is a federal funding opportunity offered by the National Institute on Drug Abuse, a component of the National Institutes of Health within the U.S. Department of Health and Human Services. This program is designed to expand the application of advanced data science techniques in substance use and substance use disorder research. The initiative reflects NIDA’s strategic priority to integrate computational, analytical, and data-driven approaches into public health research, particularly in addressing addiction, overdose, and related health outcomes such as HIV. The purpose of the D-START program is to support investigators who are transitioning into data science-oriented research in the substance use field. The program emphasizes the use of innovative methodologies such as machine learning, artificial intelligence, computational modeling, and large-scale data analytics. Projects may include pilot studies, feasibility studies, secondary analyses of existing datasets, or small-scale original data collection. The scope spans basic, clinical, translational, and implementation research, with the expectation that funded investigators will use findings to pursue larger follow-on grants such as R01 awards. Funding is structured as a small research grant under the R03 mechanism, with applicants permitted to request up to one hundred thousand dollars in direct costs per year for a maximum project period of two years. This results in a maximum potential award of two hundred thousand dollars per project. The program anticipates making approximately six to seven awards annually, with a total program funding level of about one million dollars per fiscal year. There is no cost sharing or matching requirement associated with this opportunity, allowing applicants to focus resources on research execution. Eligibility for this opportunity is broad and inclusive, encompassing a wide range of organizational types. Eligible applicants include public and private institutions of higher education, nonprofit organizations with or without tax exempt status, for profit entities including small businesses, and various levels of government including state, local, and tribal entities. Foreign organizations and non domestic components of U.S. organizations are also eligible to apply. Individual principal investigators must demonstrate the necessary expertise and resources to conduct the proposed research and must be affiliated with an eligible organization. Applications must be submitted electronically through approved federal systems such as Grants.gov, ASSIST, or institutional system to system solutions. Applicants are required to complete multiple registrations prior to submission, including SAM, Grants.gov, and eRA Commons. The application must follow the NIH Research Instructions and include required components such as a research plan, budget, and data management and sharing plan. Applications are reviewed through the NIH peer review process, where criteria include significance, innovation, rigor, feasibility, investigator expertise, and institutional environment. The application timeline follows standard NIH submission cycles with multiple due dates each year. For example, application deadlines include February 16, June 16, and October 16 annually, with corresponding review and award cycles extending several months beyond submission. Applications must be submitted by five pm local time of the applicant organization on the deadline date. The opportunity is recurring and operates on a predictable cycle, though the specific notice has been reissued and updated periodically. The most recent version indicates an expiration tied to a reissued announcement in July 2026. Program oversight includes strict compliance with NIH policies on data sharing, human subjects protections, and reporting requirements. Award recipients are expected to adhere to data management plans and may be required to register clinical trials where applicable. Contacts for the program include scientific staff within NIDA as well as general grants support offices. Investigators are encouraged to consult program officers prior to submission to ensure alignment with program priorities and responsiveness to the funding opportunity.